Integrated exposure-based therapy for co-occurring post-traumatic stress disorder and alcohol dependence: effects of the FAAH inhibitor PF-04457845 on extinction. A randomized controlled trial
Phase of Trial: Phase II
Latest Information Update: 29 Oct 2018
Price : $35 *
At a glance
- Drugs PF 4457845 (Primary)
- Indications Alcoholism; Post-traumatic stress disorders
- Focus Therapeutic Use
- 23 Oct 2018 Status changed from suspended to discontinued.
- 02 Mar 2016 Status changed from recruiting to suspended as reported by European Clinical Trials Database record.
- 19 Aug 2014 New trial record